Skip to main content
. Author manuscript; available in PMC: 2020 Sep 5.
Published in final edited form as: Cell Stem Cell. 2019 Jul 11;25(3):373–387.e9. doi: 10.1016/j.stem.2019.06.009

Figure 6. ARPKD Kidney Organoids Recapitulate Cystogenesis.

Figure 6

(A) Whole-mount immunofluorescence analysis of 3D kidney organoids (Day 24) derived from ARPKD iPSCs and corrected-ARPKD iPSCs. Scale bars, 500 μm.

(B) Representative bright-field images of 3D kidney organoids derived from H9 embryonic stem cells (ESCs), corrected-ARPKD iPSCs, and ARPKD iPSCs, in the absence or presence of forskolin (FSK)/8-br-cAMP for 3 days (Day 28 to 31). Scale bars, 500 μm.

(C) Left panels: time course whole-mount immunofluorescence analysis of ARPKD kidney organoids treated with 10 μM FSK. Right most panel: representative H&E staining image of ARPKD kidney organoid treated with 10 μM FSK for 7 days (Day 28 to 35). Scale bars, 500 μm.

(D) Immunofluorescence analysis of ARPKD kidney organoids in the absence or presence of 10 μM FSK for 3 days (Day 28 to 31) followed by in vitro dextran uptake assays. White asterisk indicates cyst. Scale bars, 50 μm.